Ceat Fund Raise of ₹3.25 Cr

Ceat Debt & Borrowing: ₹50 Cr

CEAT Limited confirmed redemption of its Rs. 50 Crore Commercial Paper on maturity dated October 23, 2026. The scheduled obligation was fulfilled on the same day.

Value

₹50.00 Cr

Ceat Other Announcement

CEAT Ltd disclosed loss of three share certificates belonging to holder G Sudarshan Pal. NSDL notified the exchanges for member reference and duplicate issuance.

Ceat Earnings Call Transcript: Key Takeaways

Ceat achieved record quarterly revenue but margins are under pressure from rising input costs and currency depreciation. Management is aggressively expanding capacity while navigating a complex transition with the Camso acquisition.

Ceat Investor Presentation: Key Takeaways

CEAT reported Q2 FY27 revenue of Rs. 4,762 Cr, up 26.2% YoY, driven by healthy volume and realization growth across segments despite EBITDA margin contraction due to raw material costs.

Ceat Management Change

CEAT Limited has appointed Mr. Sumeet Narang as a Non-Executive Independent Director for a 5-year term, effective October 14, 2026.

Ceat Q2 FY27 Results: Net Profit ₹112 Cr, Down 39.8% YoY

Ceat Ltd reported revenue from operations of ₹4,762 Cr (+26.2% YoY) and net profit of ₹112 Cr (-39.8% YoY) for Q2 FY27.

Key figure

Net profit ₹112 Cr · -39.8% YoY

Rajkot Investment Trust Fund Raise of ₹48 Cr

Rajkot Investment Trust's board approved a Rs 48 Crore rights issue of equity shares. Pricing and record date will be set later by a committee.

Value

₹48.00 Cr

U Y Fincorp Fund Raise of ₹187.2 Cr

U.Y. Fincorp's board approved preferential issues of warrants and equity shares aggregating Rs 187.17 Crore. The issue is subject to shareholder and regulatory approvals.

Value

₹187.2 Cr

Rite Zone Chemcon India Fund Raise of ₹6.58 Cr

Rite Zone Chemcon India announced a preferential issue of 27,69,730 equity shares to 11 investors at Rs.24 each, raising about Rs.6.58 Crore. The approval awaits a shareholder vote on 23 November 2026.

Value

₹6.58 Cr

Sudarshan Pharma Industries Fund Raise of ₹72 Cr

Sudarshan Pharma's board approved up to Rs. 72 Crore of preferential convertible warrants for promoters Hemal and Sachin Mehta. Shareholder approval will be sought at an EGM.

Value

₹72.00 Cr

Flywings Simulator Training Centre Fund Raise of ₹68.2 Cr

Flywings Simulator's board approved Rs. 68.20 Crore fully convertible warrants on a preferential basis. Promoter Rupal Mandavia is allotted Rs. 25 Crore, subject to shareholder approval.

Value

₹68.20 Cr

Kanel Industries Fund Raise of ₹16.99 Cr

Kanel Industries' board approved a rights issue of 42.52 lakh equity shares at Rs.39.95 each. The issue aggregates about Rs.16.99 Crore, with record date 13 November 2026.

Value

₹16.99 Cr

Execution

Rights issue opens 23 November 2026 and closes 30 November 2026